Vivos Therapeutics (VVOS) Non-Current Debt (2020 - 2026)

Vivos Therapeutics (VVOS) posted quarterly Non-Current Debt of $418000.0 for Q1 2026, down 10.87% quarter-over-quarter from $469000.0 in Q4 2025.

Vivos Therapeutics (VVOS) Non-Current Debt (2020 - 2026) Analysis & Trends

Vivos Therapeutics (VVOS) has reported Non-Current Debt for 4 consecutive years, with $418000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Non-Current Debt changed N/A year-over-year to $418000.0; the TTM figure through Mar 2026 stood at $418000.0 (changed N/A YoY), while the FY2025 annual figure was $469000.0, changed N/A from the prior year.
Non-Current Debt slipped to $418000.0 in Q1 2026 per VVOS's latest filing, from $469000.0 in the prior quarter.
Across five years, Non-Current Debt topped out at $8.4 million in Q3 2025 and bottomed at $418000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	29.60 Bn
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	14.19 Bn
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	26.17 Bn
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	10.92 Bn
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	598.70 Mn
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	-
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	10.09 Bn
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	7.34 Bn
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	1.65 Bn
10	Vivos Therapeutics	4.94 Mn	3.14 Mn	2.95 Mn	366,000.00

Download Data